A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October ...

Early disclosure of AD blood biomarker results increases diagnostic certainty and leads to earlier, more targeted clinical ...

GmbH (formerly Prosperodes GmbH), a biomarker strategy company focused on neurodegenerative diseases and other proteopathies, ...

Epatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide, with prognosis closely ...

A large global study provides new evidence supporting the use of blood biomarkers in an Alzheimer's clinical trial to screen for elevated brain amyloid levels among potential participants who are ...

BURLINGAME, Calif., October 13, 2026--āshibio presented new clinical biomarker and genetic prevalence data supporting the development of vantictumab for ADO2 at ASBMR 2026.

On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median ...

Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further ...

A mother’s physiological wellness during gestation plays a direct and defining role in fetal neurological programming, but ...

Biomarker profiles are tumor-specific and can predict sensitivity or resistance to targeted therapy or immune checkpoint inhibition, enabling more individualized treatment selection than histology ...